Spanish studies highlight scale of late presentation and its consequences for treatment
Delayed HIV treatment initiation and protease inhibitors associated with erectile dysfunction in men living with HIV
Alendronate can prevent bone loss in people starting HIV treatment
Meta-analysis finds no real difference in safety and effectiveness between tenofovir formulations
Genetics may contribute to weight gain after switching from efavirenz to an integrase inhibitor
No increased risk of diabetes with integrase inhibitors in people starting HIV treatment
Depo Provera may worsen tenofovir-related bone loss in young women
Islatravir plus doravirine maintains viral suppression for a year
Black people and women are under-represented in anti-HIV drug studies
